Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498966 · ClinicalTrials.gov registry record · Phase 2
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
A Phase 2 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00498966: Completed Phase 2 study, sponsored by AEterna Zentaris.
NCT00498966 is a Phase 2 study that has completed, run by AEterna Zentaris. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498966, a Phase 2 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: * To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor * To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor
Primary Outcome
Clinical benefit, defined as either an objective response by RECIST or PFS \>12 weeks, is a primary endpoint of the study. The clinical benefit rate together with its two-sided exact binomial 95% confidence interval will be reported.
Interventions
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00498966 record still lists
NCT00498966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Perifosine is the first listed.
NCT00498966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00498966 about?
NCT00498966 is a clinical study titled "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney". This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: * To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or ...
What is the current status of trial NCT00498966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00498966?
The interventions under investigation include: Perifosine (DRUG).
Who is sponsoring clinical trial NCT00498966?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00498966's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia